

LA JOLLA PHARMACEUTICAL CO
Form SC 13G/A
February 12, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)

La Jolla Pharmaceutical Co.

(Name of issuer)

Common Stock, par value \$0.01 per share

(Title of class of securities)

503459109

(CUSIP number)

December 31, 2001

(Date of Event which requires filing of this Statement)

Check the appropriate box to designate the rule pursuant to which
this schedule is filed:

- Rule 13d-1 (b)
- Rule 13d-1 (c)
- Rule 13d-1 (d)

CUSIP No. 503459109

13G

Page 2 of 10 Pages

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Deutsche Bank AG

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) []
(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G/A

Federal Republic of Germany

NUMBER OF SHARES	5	SOLE VOTING POWER	
		0	
BENEFICIALLY OWNED BY		SHARED VOTING POWER	
EACH	6	2,923,800	
REPORTING		SOLE DISPOSITIVE POWER	
PERSON WITH	7	0	
		SHARED DISPOSITIVE POWER	
	8	2,923,800	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,923,800*		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	8.3%**		
12	TYPE OF REPORTING PERSON		
	HC, BK, CO		

* Included in this figure are the securities reported by Deutsche Asset Management Europe GmbH and DWS Investment GmbH on the following cover pages.

** Included in this percentage are the percentages of securities reported by Deutsche Asset Management Europe GmbH and DWS Investment GmbH on the following cover pages.

CUSIP No. 503459109 13G Page 3 of 10 Pages

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Deutsche Asset Management Europe GmbH

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) []
(b) []

3 SEC USE ONLY

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G/A

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Federal Republic of Germany

NUMBER OF SHARES	5	SOLE VOTING POWER	
		0	

BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER	
		2,761,300	

	7	SOLE DISPOSITIVE POWER	
		0	

	8	SHARED DISPOSITIVE POWER	
		2,761,300	

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,761,300*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

7.8%**

12 TYPE OF REPORTING PERSON

HC

* Included in this figure are the securities reported by DWS Investment GmbH on the following cover page.

** Included in this percentage are the percentages of securities reported by DWS Investment GmbH on the following cover page.

CUSIP No. 503459109	13G	Page 4 of 10 Pages
---------------------	-----	--------------------

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

DWS Investment GmbH

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) []
(b) []

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G/A

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Federal Republic of Germany

NUMBER OF SHARES 5 SOLE VOTING POWER
0

BENEFICIALLY OWNED BY 6 SHARED VOTING POWER
1,415,000

EACH REPORTING 7 SOLE DISPOSITIVE POWER
0

PERSON WITH 8 SHARED DISPOSITIVE POWER
1,415,000

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,415,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.0%

12 TYPE OF REPORTING PERSON
CO

Item 1(a). Name of Issuer:

La Jolla Pharmaceutical Co. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

The address of the Issuer's principal executive offices is 6455 Nancy Ridge Drive, San Diego, CA 92121, United States.

Item 2(a). Name of Person Filing:

This statement is filed on behalf of Deutsche Bank AG ("DBAG"), Deutsche Asset Management Europe GmbH ("DWS Group"), DWS Investment GmbH ("DWS" and together with DBAG and DWS Group, the "Reporting Persons"). This Schedule 13G/A is being filed pursuant to Rule 13d-2(b).

Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal place of business of DBAG is Taunusanlage 12, D-60325, Frankfurt am Main, Federal Republic of Germany.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G/A

The principal place of business of DWS Group is Feldbergstrasse 22, 60323 Frankfurt, Federal Republic of Germany.

The principal place of business of DWS is Grueneburgweg 113-115, 60612, Frankfurt, Federal Republic of Germany.

Item 2(c). Citizenship:

The citizenship of the Reporting Persons is set forth on the applicable cover page.

Item 2(d). Title of Class of Securities:

The title of the securities is common stock (the "Common Stock").

Item 2(e). CUSIP Number:

The CUSIP number of the Common Stock is set forth on each cover page.

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

(a) Broker or dealer registered under section 15 of the Act;

(b) Bank as defined in section 3(a)(6) of the Act;

(c) Insurance Company as defined in section 3(a)(19) of the Act;

(d) Investment Company registered under section 8 of the Investment Company Act of 1940;

-5-

(e) An investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(E);

(f) An employee benefit plan, or endowment fund in accordance with Rule 13d-1 (b)(1)(ii)(F);

(g) A parent holding company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G);

(h) A savings association as defined in section 3(b) of the Federal Deposit Insurance Act;

(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1 (c), check this box.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G/A

Item 4. Ownership.

(a) Amount beneficially owned:

Each of the Reporting Persons owns the amount of the Common Stock as set forth on the applicable cover page.

(b) Percent of class:

Each of the Reporting Persons owns the percentage of the Common Stock as set forth on the applicable cover page.

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:

Each of the Reporting Persons has the sole power to vote or direct the vote of the Common Stock as set forth on the applicable cover page.

(ii) shared power to vote or to direct the vote:

Each of the Reporting Persons has the shared power to vote or direct the vote of the Common Stock as set forth on the applicable cover page.

(iii) sole power to dispose or to direct the disposition of:

Each of the Reporting Persons has the sole power to dispose or direct the disposition of the Common Stock as set forth on the applicable cover page.

(iv) shared power to dispose or to direct the disposition of:

-6-

Each of the Reporting Persons has the shared power to dispose or direct the disposition of the Common Stock as set forth on the applicable cover page.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owners of more than five percent of the class of securities check the following [x].1

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Investment management clients of each of the Reporting Persons have the ultimate right to any dividends from Common Stock and the proceeds from the sale of Common Stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G/A

The following are subsidiaries of DBAG and/or DWS Group which acquired Common Stock included in the figures on the cover pages: DWS Investment GmbH, DWS Investment S.A. Luxemburg, Deutsche Asset Management Investmentgesellschaft mbH.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

* As of December 31, 2001, DWS Investment GmbH has ceased to be the beneficial owner of more than five percent of the class securities

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2002

DEUTSCHE BANK AG

By:/s/ Jeffrey A. Ruiz

Name: Jeffrey A. Ruiz
Title: Vice President

By:/s/ Margaret M. Adams

Name: Margaret M. Adams
Title: Director

EXHIBIT 1

Consent of Deutsche Asset Management Europe GmbH

The undersigned agrees that the Schedule 13G executed by Deutsche Bank AG to which this statement is attached as an exhibit is filed on behalf of Deutsche Bank AG, Deutsche Asset Management Europe GmbH and DWS Investment GmbH pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934.

Dated: February 12th, 2002

DEUTSCHE ASSET MANAGEMENT
EUROPE GMBH

By:/s/ Dr. Dieter Eisele

Name: Dr. Dieter Eisele
Title: Global Head of Compliance

By:/s/ Michaela Bundschuh

Name: Michaela Bundschuh
Title: Head Position Monitoring

EXHIBIT 2

Consent of DWS Investment GmbH

The undersigned agrees that the Schedule 13G executed by Deutsche Bank AG to which this statement is attached as an exhibit is filed on behalf of Deutsche Bank AG, Deutsche Asset Management Europe GmbH and DWS Investment GmbH pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934.

Dated: February 12th, 2002

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G/A

DWS INVESTMENT GMBH

By:/s/ Dr. Dieter Eisele

Name: Dr. Dieter Eisele
Title: Global Head of Compliance

By:/s/ Michaela Bundschuh

Name: Michaela Bundschuh
Title: Head Position Monitoring